stockrowNewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024.
- Revenue
- +5,406.9%
- EPS
- +77.1%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
Follow NAMS
Alert me
NewAmsterdam Pharma Company N.V. (NAMS) EV/FCF
As of 5 November 2026, NewAmsterdam Pharma Company N.V. (NAMS) trades at a EV/FCF of −11.4×. Over the past ten years it has ranged from −262× (September 2022) to 0.0× (September 2021); the current reading is higher than 56% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −23.8× | — |
| FY2024 | −10.0× | — |
| FY2023 | −4.5× | — |
| FY2022 | −23.9× | — |
| FY2022 | −235× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −15.8× | — |
| Jun 2026 | −24.7× | — |
| Mar 2026 | −22.9× | — |
| Dec 2025 | −23.8× | — |
| 11 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| PVLA Palvella Therapeutics, Inc. compare | −62.4× |
| MBX MBX Biosciences, Inc. compare | −22.3× |
| NAMS NewAmsterdam Pharma Company N.V. | −11.4× |
| XNCR Xencor, Inc. compare | −10.8× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −10.5× |
| PHVS Pharvaris N.V. compare | −10.5× |
| CLDX Celldex Therapeutics, Inc. compare | −6.2× |
| RXRX Recursion Pharmaceuticals, Inc. compare | −4.3× |
| ADMA ADMA Biologics Inc compare | 25.2× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on NAMS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement